Characteristics of Real-World Patients with High-Risk <em>BRAF</em><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Original Research

Characteristics of Real-World Patients with High-Risk BRAF^V600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Total article views		HTML views	PDF downloads	Totals
2,600	Dovepress*	2,514+	82	2,596
	PubMed Central*	86	47	133
	Totals	2,600	129	2,729
*Since 11 November 2023

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
2	0	0	0	1	1